On Feb. 7, CLSA held its annual Back to Session Reception to welcome legislators back to Sacramento for the commencement of another legislative year, as well as to honor those legislators identified by CLSA membership as Life Sciences Champions. Dozens of legislators and at least two hundred other attendees packed the Ella Dining Room and Bar to see the presentation and mingle with those representing the life sciences industry, among others.
This month (February 9), Congress passed and the President signed into law a full and permanent repeal of the Independent Payment Advisory Board (IPAB). Eliminating the IPAB is critical for the continued success of California’s innovative life sciences sector, because the board could have harmed biomedical innovation by reducing incentives for investment in new research and product development.
Following the Feb. 16 deadline for submitting new legislation to be considered for enactment this year, CLSA expects to see more than a dozen bills related to opioids when the dust settles. The ultimate number of bills dealing with the subject will not be apparent immediately, as many are introduced in a generic format, which is called a “spot bill,” and later amended with more specific language.
Legislators Honored with Award for Commitment to Strengthening California Life Sciences Sector at CLSA’s Back to Session Reception in Sacramento
On Jan. 18, Assemblymembers Kevin McCarty (D-Sacramento) and Phil Ting (D-San Francisco) introduced Assembly Constitutional Amendment 22, which would raise corporate taxes on California companies with annual net revenues higher than $1 million. The state tax increase on these corporations is intended to be equivalent to half of the federal tax cut recently signed into law.
On Jan. 22, Congress passed a 2-year suspension of the medical device excise tax, retroactive to Dec. 31, 2017, providing much-needed relief for California’s medical device sector.
While several opioid-related bills were introduced last year in California’s legislature, many in Sacramento anticipate a double-digit number of opioid-related bills to be introduced this year.
CLSA, the trade association representing California’s life sciences industry, today commended the U.S. Senate’s confirmation of Alex Azar as the new secretary of the U.S. Department of Health and Human Services (HHS).
California Life Sciences Association (CLSA) applauds the House and Senate passage of legislation that temporarily suspends the ill-conceived 2.3% medical device tax for an additional 2 years, until December 2019.
CLSA today issued the following statement applauding Governor Jerry Brown’s 2018 – 2019 California budget proposal that calls for $30 million to be invested in precision medicine research and the establishment of the California Institute to Advance Precision Health and Medicine (CIAPHM).